Dissertations / Theses on the topic 'Inhibiteurs de pompe à protons'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 27 dissertations / theses for your research on the topic 'Inhibiteurs de pompe à protons.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Guérard, Françoise. "Une nouvelle classe d'antiulcéreux : les inhibiteurs de la pompe à protons." Paris 5, 1989. http://www.theses.fr/1989PA05P086.
Barjou, Agnès. "Les inhibiteurs de la pompe à protons dans la thérapeutique de l'ulcère gastroduodénal." Bordeaux 2, 1995. http://www.theses.fr/1995BOR2P018.
KRAUSER, SABINE. "L'omeprazole, un inhibiteur de la pompe a protons." Université Louis Pasteur (Strasbourg) (1971-2008), 1990. http://www.theses.fr/1990STR15073.
Jebbari, Mostafa. "Les inhibiteurs de la pompe à protons, l'ulcère gastroduodénal à l'heure de l'Helicobacter Pylori." Bordeaux 2, 1998. http://www.theses.fr/1998BOR2P025.
Montrichard, Françoise. "Mise au point d'une méthode pour l'isolement des vacuoles et propriétés de l'ATPase pompe à protons du tonoplaste d'acer pseudoplatanus." Besançon, 1990. http://www.theses.fr/1990BESA2026.
Poquet, Sandrine. "Un nouvel inhibiteur de la pompe à protons : le prantoprazole." Bordeaux 2, 1998. http://www.theses.fr/1998BOR2P047.
Loui͏̈a, Franck. "Les inhibiteurs des "pompes" à protons gastriques : recherches, développements, synthèses chimiques, mécanismes d'action et relations structure-activité." Paris 5, 1994. http://www.theses.fr/1994PA05P253.
El, Chamieh Carolla. "Influence des toxines urémiques sur la morbi-mortalité cardiovasculaire des patients en Maladie Rénale Chronique dans la cohorte CKD-REIN." Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASR003.
Chronic kidney disease (CKD) is a major public health problem, affecting more than 10% of the worldwide adult population. Patients with CKD have an increased risk of cardiovascular morbidity and mortality, highlighting the importance of identifying associated risk factors. Uremic toxins (UTs) are molecules that accumulate in patients with CKD, and which have been identified as cardiovascular risk factors specific to CKD. A narrative review, including all in vitro, in vivo, and observational studies between 2002 and 2022 evaluating the link between UTs and cardiovascular risk, was carried out at the beginning of the thesis. This allowed us to conclude that kynurenine, a protein-bound UT derived from tryptophan metabolism, has never been studied in pre-dialysis patients. Thus the second objective of the thesis evaluated the association between kynurenine and cardiovascular events. Furthermore, it is crucial to identify factors that may influence serum concentrations of UTs, for which available information is limited. Proton pump inhibitors (PPIs), commonly prescribed for patients with CKD, and certain UTs are eliminated by the organic anion transporters in the kidneys. The hypothesis of a potential interaction between PPIs and UTs has never been assessed in the literature. Hence, our last objective was to evaluate their association. The last two objectives of the thesis were conducted using data from the CKD-REIN cohort, a large prospective cohort carried out in 40 nephrology clinics in France, including patients with moderate-to-advanced CKD. We found that a doubling of serum free kynurenine levels was associated with an 19%-increased hazard of cardiovascular events (466 events, HR[95%CI]: 1.19 [1.03-1.39]), independently of glomerular filtration rate, serum free tryptophan level or other UTs, cardioprotective drugs and traditional cardiovascular risk factors. Serum free kynurenine was particularly associated with non-atheromatous cardiovascular events (HR[95%CI]: 1.31 [1.09-1.6]). However, we did not find a significant association between serum free kynurenine and all-cause mortality (311 events,HR[95%CI]: 1.18 [0.9-1.4]). In a randomly selected sub-cohort from CKD-REIN, 31% of patients had PPI prescriptions at baseline. We demonstrated that serum concentrations of free and total indoxyl sulfate, free and total p-cresyl glucuronide, and phenylacetylglutamine were significantly and independently higher in patients taking PPIs compared to those who were not. This thesis highlights the need for further research to understand the underlying mechanisms of the effect of UTs on cardiovascular health in patients with CKD and to develop new treatments and approaches to mitigate their impact on the health of these patients
Tisseyre, Mylène. "Identification d'expositions médicamenteuses in utero associées à la survenue d'infections au cours de la première année de vie." Electronic Thesis or Diss., Université Paris Cité, 2023. http://www.theses.fr/2023UNIP5294.
Infant infections are a major concern in terms of global morbidity and mortality, significantly contributing to infant deaths, particularly through respiratory infections. Risk factors for severe infections in infants are multifactorial, primarily related to in utero development, prematurity, low birth weight, as well as immunological, genetic, and environmental factors. Recent data in the literature suggest that modifications in the microbiome can have immunological implications and potentially increase the risk of infection. Therefore, changes in the maternal-fetal microbiome could have consequences for the infant. Recent literature suggests associations between in utero exposure to antibiotics and an increased risk of serious infections in early childhood. These studies have been made possible, in particular, through the development of pharmacoepidemiology using medical-administrative databases, such as the National Health Data System (SNDS), allowing the creation of substantial cohorts of pregnant women. The overall objective of this thesis was to evaluate the role of medication exposures during pregnancy and the risk of serious infections in the first year of life. The research work focused on two pharmacological classes due to their frequent use during pregnancy and their impact on the maternal-fetal microbiome: antibiotics and proton pump inhibitors. Firstly, a national cohort study, including 2.8 million full-term infants, evaluated the association between in utero exposure to systemic antibiotics and the occurrence of serious infections in full-term infants during their first year of life. The results revealed a moderate increase in the incidence of serious infections in infants exposed in utero to systemic antibiotics. Associations were similar regardless of the trimester of exposure, antibiotic class, and infection sites. However, infants exposed to broad-spectrum antibiotics or three or more antibiotic courses appeared to have a slightly increased risk, supporting a potential causal relationship. Secondly, another study, stratified by the use of proton pump inhibitors during the first three months of life and including 2.1 million full-term infants, explored the impact of prenatal exposure to proton pump inhibitors on the occurrence of serious infections during their first year of life. The results ruled out a significant association between the use of proton pump inhibitors during pregnancy and the occurrence of serious infections in infants. Nevertheless, even after adjusting for several confounding factors, this study did not exclude a limited residual risk, restricted only to infants with proton pump inhibitors use in early life. In conclusion, this thesis confirmed existing data on an association between exposure to antibiotics during pregnancy, which strongly affects the microbiome, and the occurrence of serious infections in infants. The results are more reassuring concerning proton pump inhibitors; although a low risk cannot be completely ruled out. These findings need confirmation through further studies. They have contributed to expanding the knowledge regarding the safety of medication use during pregnancy
Rodier, Jean-Gilles. "Inhibiteur de la pompe à protons contre Nissen par laparoscopie : une évaluation médico-économique du traitement du refluxgastro-oesophagien de l'adulte selon un modèle de Markov." Montpellier 1, 1999. http://www.theses.fr/1999MON11082.
Grout, Emmanuelle. "Anti-ulcéreux : apport des nouvelles classes thérapeutiques dans le traitement des ulcères : application à des cas cliniques, règles hygiéno-diététiques des ulcères." Paris 5, 1992. http://www.theses.fr/1992PA05P174.
Verley, Bénédicte. "Bon usage des anti-ulcéreux." Paris 5, 2001. http://www.theses.fr/2001PA05P023.
Magnin, Thierry. "Proprietes physico-chimiques et mecanisme reactionnel de l'atpase pompe a protons du tonoplaste d'acer pseudoplatanus." Besançon, 1993. http://www.theses.fr/1993BESA2034.
El, Kouki El Khansa. "Relations entre l'activité de la pompe à protons et l'absorption du nitrate dans la racine." Montpellier 2, 1990. http://www.theses.fr/1990MON20148.
FRAICHARD, ANNICK. "Proprietes physico-chimiques et regulation de la pyrophosphatase pompe a protons du tonoplaste d'acer pseudoplatanus." Besançon, 1993. http://www.theses.fr/1993BESA2028.
Marquez-Garrido, Béatrice. "Criblage antibactérien par une chimiothèque de molécules : recherche d' inhibiteurs de deux systèmes d' efflux chez Staphylococcus aureus : les pompes NorA et Msr(A)." Paris 6, 2005. https://pastel.archives-ouvertes.fr/pastel-00001618.
Hernández, Jessica. "Design et synthèse de nouveaux inhibiteurs de la résistance bactérienne ciblant la pompe d'efflux AcrAB-ToIC chez Enterobacter aerogenes." Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5508.
Overexpression of Resistance-Nodulation-Division (RND) efflux pumps (EP) is a major contributor in multidrug resistance (MDR) and pathogenicity in Gram-negative bacteria. These transporters are able to expel out of the bacterial cell clinically important antibiotic classes, contributing in a significant manner to the treatment failure of infectious diseases. With the worrying levels of bacterial resistance reported worldwide and the continuous spreading of MDR pathogens, EPs are interesting targets for the discovery of new antimicrobial drugs. Therefore, to overcome this mechanism, efflux pump inhibitors (EPIs) are being developed as adjuvants in order to restore or improve the activity of usual antibiotics. The AcrAB-TolC archetype is particularly widespread in Enterobacter spp. presenting clinical relevance (ESKAPE pathogens). In this study, we described the drug design strategy based on fluoroquinolone antibiotic analogs, against the AcrB pump of E. aerogenes. Thus, synthesis and microbiological evaluation of quinazolin-4(3H)-one derivatives were performed. The structural and molecular properties of the tested compounds (i. e. rigidity and flexibility) were also investigated. In this purpose, a scaffold hopping of the quinazolinone core to homologous benzoquinazolinones and precursors benzamides were carried out. Several molecules increased the bacterial susceptibility towards norfloxacin and chloramphenicol. The obtained results, supported by molecular modeling, suggest that molecular flexibility and the nature of chemical functions play a critical role to improve activity and selectivity on fluoroquinolone potentiation targeting AcrB efflux pump
Hernández, Jessica. "Design et synthèse de nouveaux inhibiteurs de la résistance bactérienne ciblant la pompe d'efflux AcrAB-ToIC chez Enterobacter aerogenes." Electronic Thesis or Diss., Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5508.
Overexpression of Resistance-Nodulation-Division (RND) efflux pumps (EP) is a major contributor in multidrug resistance (MDR) and pathogenicity in Gram-negative bacteria. These transporters are able to expel out of the bacterial cell clinically important antibiotic classes, contributing in a significant manner to the treatment failure of infectious diseases. With the worrying levels of bacterial resistance reported worldwide and the continuous spreading of MDR pathogens, EPs are interesting targets for the discovery of new antimicrobial drugs. Therefore, to overcome this mechanism, efflux pump inhibitors (EPIs) are being developed as adjuvants in order to restore or improve the activity of usual antibiotics. The AcrAB-TolC archetype is particularly widespread in Enterobacter spp. presenting clinical relevance (ESKAPE pathogens). In this study, we described the drug design strategy based on fluoroquinolone antibiotic analogs, against the AcrB pump of E. aerogenes. Thus, synthesis and microbiological evaluation of quinazolin-4(3H)-one derivatives were performed. The structural and molecular properties of the tested compounds (i. e. rigidity and flexibility) were also investigated. In this purpose, a scaffold hopping of the quinazolinone core to homologous benzoquinazolinones and precursors benzamides were carried out. Several molecules increased the bacterial susceptibility towards norfloxacin and chloramphenicol. The obtained results, supported by molecular modeling, suggest that molecular flexibility and the nature of chemical functions play a critical role to improve activity and selectivity on fluoroquinolone potentiation targeting AcrB efflux pump
Davidian, Jean-Claude. "L'excrétion de H+ par la racine : contrôles ioniques et métaboliques de la pompe à H+ de la racine d'orge." Montpellier 2, 1986. http://www.theses.fr/1986MON20171.
Nolibe, Anne-Laure. "Etude du pouvoir inhibiteur du sérum d'insuffisants rénaux sur la pompe Na-K-ATPase." Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P097.
Ouhabi, Rachid. "Rendement des pompes à protons impliquées dans les oxydations phosphorylantes chez les mitochondries de la levure Saccharomyces cerevisiae : variation en fonction du flux." Bordeaux 2, 1992. http://www.theses.fr/1992BOR28181.
Fitton, Valérie Catherine. "Etudes comparées du métabolisme énergétique des mitochondries isolées et des cellules perméabilisées de la levure S. Cerevisiae." Bordeaux 2, 1996. http://www.theses.fr/1996BOR28438.
Jumelle-Laclau, Muriel. "Modifications de la stœchiométrie des systèmes transducteurs d'énergie des mitochondries isolées de foie de rat : effets des découplants et de l'almitrine en fonction de l'âge." Bordeaux 2, 1993. http://www.theses.fr/1993BOR28247.
Harmand, Marion. "Spectroscopie d'absorption X résolue en temps pour l'étude de la matière dense et tiède." Phd thesis, Université Sciences et Technologies - Bordeaux I, 2009. http://tel.archives-ouvertes.fr/tel-00720159.
Compagne, Nina. "Développement d'inhibiteurs des pompes d'efflux des bactéries Gram négatives pour lutter contre la résistance aux antibiotiques." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS032.
The discovery of antibiotics in the 20th century allowed to treat a number of previously fatal bacterial infectious diseases. However, this therapeutic progress was followed by a massive, repeated and inappropriate use of antibiotics, leading to the rise of antimicrobial resistance. This phenomenon is alarming, with an estimated 4.95 million deaths associated with antibiotic resistance in 2019. One of the resistance mechanisms developed by Enterobacterales and overall Gram-negative bacteria is the (over)expression of efflux pumps. These bacterial pumps are able to extrude several classes of antibiotics, thereby reducing their intrabacterial concentration and rendering them ineffective. One strategy being considered to circumvent this phenomenon is the development of efflux pump inhibitors which, in combination with an antibiotic, could offer a new therapeutic alternative to treat resistant bacterial infections.AcrAB-TolC is an efflux pump of the RND superfamily found in Enterobacterales such as Escherichia coli and Klebsiella pneumoniae. In order to identify inhibitors of this pump, a chemical library of 1280 fragments was screened on E. coli in combination with a model antibiotic substrate of this pump, leading to the selection of a hit compound belonging to the pyridylpiperazine family. This hit has no intrinsic antibacterial activity, but is able to potentiate the activity of a range of antibiotics by direct inhibition of the AcrB protein. Initial studies of structure-activity relationships have allowed the identification of two chemical series, the quinoline/quinoxaline series and the pyridine series. Structural modifications around these three cores were carried out using a rational design based on the co-crystallographic structures obtained with AcrB. 80 compounds were therefore synthesised in order to identify more potent analogues and establish new structure-activity relationships. In particular, the introduction of different substituents with an amine function allowed to create new interactions with acidic residues in the AcrB binding pocket. The physicochemical and in vitro pharmacokinetic parameters of the most promising compounds were then measured, leading to the selection of one compound for a pharmacokinetic study in mice. In order to enrich the chemical diversity of substituents introduced on the quinoline and pyridine rings, a chemical library of 672 triazoles was synthesised via a copper-catalysed cycloaddition reaction. The aim was to increase the potency of the compounds by creating new interactions with AcrB while reducing the cytotoxicity and intrinsic antibacterial activity of the compounds. This led to the identification of new compounds with promising activities, which will soon be resynthesised in order to characterise their biological effect and measure their ADME properties
Gleize, Vincent. "Etude des sous-unités a de la v-ATPase : caractérisation de leurs interactions avec les protéines SNAREs et étude de l’expression par des gliomes de la sous-unité rénale a4." Thesis, Paris 11, 2011. http://www.theses.fr/2011PA11T052.
Vacuolar type H+-ATPase is a proton pump, which acidifies numerous organelles, crucial for many cellular processes. This enzyme is composed of 14 different subunits organized in two domains, a catalytic V1 domain and a V0 membrane domain. The a-subunit of V0 is essential for proton transport. There are 4 isoforms of a (a1 to a4) and splicing variants (a1-I to a1-IV for the a1 subunit). v-ATPases containing different a-subunit isoforms are localized in different compartments allowing v-ATPase to participate in different processes. The a-subunits were studied in this work in two distinct projects.Besides its role in proton pumping, V0 domain of v-ATPase is implicated in organelles trafficking events, like vesicles exocytosis. This role seems to require interactions of V0 with SNARE proteins. During my thesis work, I showed that flag-a1-I and flag-a1-IV are both targeted to secretion granules in PC12 neurosecretory cells. These subunits interact with the SNARE proteins VAMP2 and syntaxin-1. Interestingly, syntaxin-1 seems to preferentially interact with the a1-I subunit, isoform which in neurons is sorted to nerve terminals. The only difference between a1-I and a1-IV subunits is the addition of 7 amino acids in the N-terminal half of a1-IV. So syntaxin-1 probably interacts with a1-I at this location. In a second project, I studied the expression of the renal a4-subunit in human gliomas. These tumors are the most frequent brain tumors and are generally associated with a poor prognosis. Based on histological parameters,WHO distinguishes, astrocytomas (grade I to IV), oligodendrogliomas and oligoastrogliomas (each of grade II or III). This classification suffers of a lack of reproducibility, which could be overcome by the identification of specific molecular markers.In the present work, by real time quantitative PCR, ATP6V0A4 gene (encoding the renal a4) expression was quantified in 188 human glioma biopsies. We established a4 expression as a new marker of grade III oligodendrogliomas (35 % express it), independent of the 1p/19q codeletion, an established marker of oligodendrogliomas. Moreover, a4 is expressed in 70% of pilocytic astrocytomas, in which it is associated with the tandem duplication of 7q34, localized at direct proximity of the ATP6V0A4 gene. Of promising interest is the observation that a4 expression could be considered as a bad prognostic marker for patients with 1p/19q non-deleted oligodendrogliomas, an observation that should be confirmed on larger cohorts of patients
Beaulieu, Mathieu. "Les inhibiteurs de pompes à protons comme facteur de risque pour les diarrhées à Clostridium difficile chez des patients de soins intensifs." Thèse, 2005. http://hdl.handle.net/1866/15634.